HeartWare International Reports Third Quarter Revenues of $7... (uted share compared to a $19.8 million n...)

HeartWare International Reports Third Quarter Revenues of $7.5 Million

Date:11/4/2009

uted share, compared to a $19.8 million net loss, or a loss of $2.61 per basic and diluted share, in the prior year nine-month period. These figures include a $2.2 million (non-cash) charge recorded during the 2009 period associated with a change in the fair value of a derivative instrument embedded in the $20 million loan facility provided by Thoratec Corporation.

Godshall continued, "We are making the necessary investments in our operating infrastructure, staffing and clinical trials so as to lay the foundation for our continued growth."

The balance sheet was strengthened during the third quarter as a result of a $60 million private placement of common stock entered into in mid August 2009. At September 30, 2009 the balance sheet showed $31.4 million in cash and cash equivalents, with the outstanding $30.7 million of the $60 million private placement having been released from escrow to the Company following stockholder approval of the private placement on October 26, 2009.

The Company will host a conference call on Thursday, November 5, 2009 at 8:00 a.m. U.S. Eastern time (being 12:00 a.m. Australian Eastern Daylight Time between November 5 and 6, 2009) to discuss its third quarter results. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial +1-201-689-8471. Doug Godshall, Chief Executive Officer, President and Executive Director, and David McIntyre, Chief Financial Officer and Chief Operating Officer, will host the conference call.

A live web cast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter and Nine Months Conference Call" under the section titled "Corporate Presentations" on the HOME page. A replay of the conference call will be available through the above weblink immediately f
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

Post Your Comments:

HeartWare International Reports Third Quarter Revenues of $7...(uted share compared to a $19.8 million n...),Health